Bernard Conrad and Bernard Mach U.S. Serial No. Not Yet Known (continuation of PCT/EP98/04926 filed July 22, 1998) Filed: Herewith Page 19

A3

step iii) in conjunction with primers specific for the poly(A) signals present in the 3' R-poly(A) sequences isolated in step ii); and

- vi) confirming [confirmation of] the presence of an intact retroviral genome by amplification using primers specific for its predicted U5 and U3 regions.--
- --60. (Amended) <u>A process</u> [Process] according to claim 59 further comprising a step vii) of detecting SAg activity associated with the retrovirus, or portions thereof, said detection being carried out according to claim 58.--
- --61. (Amended) <u>A transgenic</u> [Transgenic] animal including in its genome non-human cells according to claim 35.--

REMARKS

This application is a continuation of PCT International Application No. PCT/EP98/04926, filed 22 July 1998, designating the United States of America and claiming priority of European Application Nos. 97112482.1, filed July 22, 1997 and 97401773.3, filed July 23, 1997.


By this Preliminary Amendment, applicants have amended the specification to recite the continuing data for the above-identified application. The amendments to the specification at pages 15, 41, 42, 47-49, and 73-77 to include the appropriate sequence identifiers (SEQ ID NOS.) are made to bring the specification of the subject application into compliance with 37 C.F.R. §§1.821 through 1.825. Accordingly, applicants maintain that the amendments to the specification raises no issue of new matter and respectfully request that this Amendment be entered.

Christophe Gerald, et al. U.S. Serial No. 09/328,314 Filed: April 3, 1998 Page 20

By this Amendment, applicants have amended claims 1-51 and 53-61. Accordingly, upon entry of this Amendment, claims 1-61 will be pending and under examination. Applicants maintain that amended claims 1-51 and 53-61 raise no issue of new matter.

By this Amendment, applicants submit a paper copy and computer readable copy of the nucleotide and/or amino acid sequences disclosed in the application in order to fulfill the requirements of 37 C.F.R. §§1.821 through 1.825 in connection with this application. Applicants submit herewith nineteen (19) pages of Sequence Listing, in compliance with the requirements of §§1.821 through 1.825, attached hereto as **Exhibit A.** Please replace original Sequence Listing pages 1-27 with new pages 1-19 attached hereto as **Exhibit A.**

Applicants also submit herewith a formatted Sequence Listing in a computer readable form which complies with the requirements of 37 C.F.R. §1.824. In addition, applicants submit a Statement in Accordance with 37 C.F.R. §1.821(f), attached hereto as **Exhibit** B, certifying that the computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which is submitted as "Sequence Listing".



If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

No fee, other than the enclosed filing fee of \$1026.00, is deemed necessary in connection with this Preliminary Amendment. However, if any other fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White Reg. No. 28,678

Attorney for Applicants Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400